- Price
- $10.52
- Day
- +4.62%
- Mkt Cap
- $621.89M
- 52W Range
- $7.16 – $15.04
- Volume
- 1.28M
- Beta
- 0.92
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra's executive leadership team will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 11:00 a.m. ET. Additionally, management will be available for one-on-one meetings with registered conference attendees.
Read full article
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. (“Zevra” or the “Company”) (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read full article
Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cocrystal Pharma (NASDAQ: COCP - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation. Institutional and Insider Ownership 35.0% of Zevra
Read full article
Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population Longitudinal study includes first published real-world data on arimoclomol in adults with NPC and provides insights across a broad patient population
Read full article
Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the July 24, 2026 negative opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use ("CHMP"). NEW YORK, Aug. 3, 2026 /PRNewswire/ -- On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency's CHMP issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C.
Read full article
Zevra Therapeutics investors saw shares fall after European regulators issued a negative opinion on arimoclomol. The investigation focuses on Zevra's regulatory statements and the July 24, 2026 CHMP decision. Zevra Therapeutics investors saw shares fall after European regulators issued a negative opinion on arimoclomol. The investigation focuses on Zevra's regulatory statements and the July 24, 2026 CHMP decision.
Read full article
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read full article
NEW YORK--(BUSINESS WIRE)--On July 24, 2026, Zevra Therapeutics (NASDAQ: ZVRA) shares fell approximately 24% after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on the Marketing Authorization Application for arimoclomol, branded Meplyffa, for Niemann-Pick disease type C. Investors who suffered losses tied to the ZVRA drop are encouraged to submit your loss information now or contact Levi & Korsinsky, LLP | (212) 363-7500 | www.zlk.c.
Read full article
LOS ANGELES--(BUSINESS WIRE)---- $ZVRA--ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law.
Read full article
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
Read full article
Zvera investors saw shares fall roughly 24% after European regulators issued a negative CHMP opinion on arimoclomol. The investigation focuses on whether investors who suffered losses may have potential securities law claims tied to the July 24, 2026 selloff.
Read full article
Shares of Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) gapped down prior to trading on Friday. The stock had previously closed at $12.52, but opened at $9.21. Zevra Therapeutics shares last traded at $10.04, with a volume of 2,268,927 shares changing hands. Analysts Set New Price Targets ZVRA has been the topic of
Read full article